WASHINGTON (AP) -- Federal health regulators say its unclear whether Genentech's blockbuster cancer drug Avastin significantly shrinks the deadliest form of brain tumor.
The Food and Drug Administration is reviewing the company's drug for a type of brain cancer that is generally fatal within six months.
South San Francisco, Calif.-based Genentech has asked the FDA to give its drug accelerated approval. That designation gives market access based on promising early results.
However regulators say it's unclear whether the company's results are strong enough to rush out the new approval. The company's application relies on imaging scans of patient's tumors.
(Copyright 2009 by The Associated Press. All Rights Reserved.)